Implantica AG

Implantica AG is a MedTech group dedicated to integrating advanced technology into the human body to address significant health conditions and enhance patient quality of life. The company's mission is to provide effective medical implant solutions, reduce healthcare costs, and improve efficiency. Headquartered in Vaduz, Liechtenstein, Implantica aims to revolutionize medical treatments through smart implants and eHealth technologies.

Implantica's flagship product is RefluxStop™, a CE-marked passive implant designed to prevent gastroesophageal reflux disease (GERD) by restoring the body's natural anti-reflux barrier. Beyond RefluxStop, the company is developing a pipeline of smart medical implants and eHealth solutions, including the e-InVivo™ implantable eHealth platform for health parameter monitoring, a Wireless Energizing Platform for remote-controlled implants, AppetiteControl™ for obesity, and UriControl® and UriRestore® for urinary incontinence and retention, respectively. These innovations primarily target the urology and digestive surgery market segments.

Led by founder and CEO Dr. Peter Forsell, Implantica is actively expanding the market presence of RefluxStop, having recently secured over EUR 1.2 million in public tender approvals in Italy and establishing its 20th RefluxStop Center of Excellence in Spain in June 2026. The company has also announced breakthrough long-term clinical data for RefluxStop, presented at DDW 2026, and received favorable feedback from the U.S. FDA on its PMA submission for U.S. market approval. Implantica positions itself as a leader in the smart implant revolution, aiming to redefine medical treatment paradigms.